Cancer cell: Linking oncogenic signaling to molecular structure

Multiscale Cancer Modeling

Volumn , Issue , 2010, Pages 31-43

  Purvis, Jeremy E ^a   Shih, Andrew J ^b   Liu, Yingting ^b   Radhakrishnan, Ravi ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901759434     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/b10407     Document Type: Chapter

References (18)

1. Agrawal, N., J. Weinstein, et al. (2008). Landscape of membrane-phase behavior under the influence of curvature-inducing proteins. Mol. Phys. 106: 1913-1923.
2. Aldridge, B. B., J. M. Burke, et al. (2006). Physicochemical modelling of cell signalling pathways. Nat. Cell Biol. 8(11): 1195-203.
3. Choi, S. H., J. M. Mendrola, et al. (2007). EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer. Oncogene 26(11): 1567-76.
4. Citri, A. and Y. Yarden (2006). EGF-ERBB signalling: towards the systems level. Nat. Rev. Mol. Cell Biol. 7(7): 505-16.
5. Hanahan, D. and R. A. Weinberg (2000). The hallmarks of cancer. Cell 100(1): 57-70.
6. Hlavacek, W. S., J. R. Faeder, et al. (2006). Rules for modeling signal-transduction systems. Sci. STKE 2006(344): re6.
7. Liu, Y., J. Purvis, et al. (2007). A multiscale computational approach to dissect early events in the Erb family receptor mediated activation, differential signaling, and relevance to oncogenic transformations. Ann. Biomed. Eng. 35(6): 1012-25.
8. Mendelsohn, J. and J. Baselga (2000). The EGF receptor family as targets for cancer therapy. [Review] [155 refs]. Oncogene 19(56): 6550-65.
9. Morris, G. M., D. S. Goodsell, et al. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Computational Chem. 19(14): 1639-1662.
10. Purvis, J., V. Ilango, et al. (2008). Role of network branching in eliciting differential short-term signaling responses in the hypersensitive epidermal growth factor receptor mutants implicated in lung cancer. Biotechnol. Prog. 24(3): 540-53.
11. Sharma, S. V. and J. Settleman (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 21(24): 3214-31.
12. Shih, A. J., J. E. Purvis, et al. (2008). Molecular systems biology of ErbB1 signaling: bridging the gap through multiscale modeling and high-performance computing. Mol. BioSyst. 4(12): 1151-1159.
13. Sjoblom, T., S. Jones, et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314(5797): 268-274.
14. Sordella, R., D. W. Bell, et al. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687): 1163-7.
15. Szabo, A. and N. S. Ostlund (1996). Modern Quantum Chem. Mineola, New York, Dover Publications.
16. Tracy, S., T. Mukohara, et al. (2004). Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64(20): 7241-4.
17. Zhang, X., J. Gureasko, et al. (2006). An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6): 1137-49.
18. Zhivotovsky, B. and G. Kroemer (2004). Apoptosis and genomic instability. Nat. Rev. Mol. Cell Biol. 5(9): 752-62.